Bayer's Profit Recovery
Bayer returns to quarterly profit, driven by robust agriculture and lower costs
Anonymous
Key Points
1
Other operating expenses fell to €569 million in the quarter, down from €2.11 billion a year earlier, a major contributor to the improved profit trajectory.
2
Earnings before interest and taxes (EBIT) jumped to €827 million from €13 million a year earlier, and EBIT before items rose to €999 million from €994 million, signaling a strong earnings recovery beyond the headline net income.
3
Crop Science sales reached €4.91 billion, up from €4.78 billion, with volumes up about 2.6% and prices up roughly 0.9%, highlighting volume-led growth alongside price effects.
4
The US re-approval of dicamba-based products boosted sales of soybean and cotton seeds within Crop Science, contributing to thequarter’s strength in agriculture.
5
Pharmaceuticals and Consumer Health still faced headwinds from patent expirations, with Xarelto and Eylea revenue declines offset by growth from newer medicines Nubeqa (prostate cancer) and Kerendia (kidney disease).
Bayer swung back to profit in the second quarter, posting net income of €219 million — a sharp reversal from a €199 million loss a year earlier, according to Yahoo Finance. The turnaround was driven by booming sales in its Crop Science unit and a dramatic drop in legal costs tied to its long-running glyphosate litigation.
Other operating expenses fell to €569 million from €2.11 billion a year earlier — a drop of roughly €1.5 billion — clearing the way for a strong earnings recovery, MarketScreener reported. Sales rose just over 1% to €10.87 billion for the quarter.
Crop Science Powers the Profit Comeback
Crop Science was the engine of the quarter. Sales reached €4.91 billion, up from €4.78 billion a year earlier, Head Topics reported. Volumes grew about 2.6% and prices rose roughly 0.9%, meaning growth was mostly volume-led. Core earnings in the division jumped about 30%.
A key boost came from dicamba-based products. The US re-approved dicamba herbicides, lifting sales of soybean and cotton seeds that work alongside the weedkiller, according to The Edge Malaysia. Glyphosate herbicide sales also climbed about 12.6%, helped by strong demand in Europe, the Middle East, and Africa.
Glyphosate Legal Saga Moves Toward a Close
Bayer has spent more than $10 billion settling glyphosate lawsuits. The company is now pushing toward a $7.25 billion class-action settlement. A recent US Supreme Court ruling helped shield Bayer from certain claims, giving the company firmer legal ground.
CEO Bill Anderson said the containment strategy is "in a strong place with milestones ahead," according to Free Malaysia Today. EBIT — earnings before interest and taxes — jumped to €827 million from just €13 million a year earlier, signaling the legal cloud is lifting fast.
Pharma Unit Stumbles as Key Patents Expire
Not everything went smoothly. Pharmaceuticals and Consumer Health both faced pressure from expiring patents. Revenue from Xarelto, a blood thinner, and Eylea, an eye treatment, fell. Patent expiry means cheaper generic rivals can enter the market and eat into sales.
Newer drugs helped cushion the blow. Nubeqa, a prostate cancer treatment, and Kerendia, used for kidney disease, both posted growth, Head Topics reported. But the pharma drag reinforced a clear shift in Bayer's story — agriculture, not pills, is carrying the company right now.
Bayer Reaffirms 2026 Targets, Eyes Debt Reduction
Bayer reconfirmed its full-year 2026 outlook after the strong quarter. The company is targeting sales of €44.7 billion to €46.7 billion, with flat-to-modest growth in core earnings per share, according to Yahoo Finance. The post-Supreme Court focus has shifted squarely to paying down debt and rebuilding long-term profitability.
MarketScreener noted the company is also accelerating debt reduction. With litigation costs falling, agriculture booming, and guidance intact, Bayer looks to be turning a corner — though pharma headwinds and remaining legal obligations still loom in the background.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
24
Reach
34
Topics
A
AnonymousAuthor
